Compare Abbott Laboratories (ABT) vs Avient Corporation (AVNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Avient Corporation — how do they compare? Abbott Laboratories trades at $109.35 (market cap $187.95B), while Avient Corporation trades at $45.51 (market cap $4.17B). The key difference: Abbott Laboratories is far larger — about 45.1× Avient Corporation's market cap, and Avient Corporation pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| ABT | AVNT | |
|---|---|---|
Market Cap | $187.95B | $4.17B |
Sector | Health | Technology |
52-Week High | $136.62 | $45.69 |
52-Week Low | $82.57 | $27.48 |
Enterprise Value | $214.96B | $5.62B |
Dividend Yield | 2.32% | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $109.74, up 1.8% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent financials show revenue growth to $44.33 billion in 2025, though net income declined to $6.52 billion. Key developments include a CE Mark for dual glucose-ketone sensors, enhancing its diabetes care portfolio. The stock is near its 52-week high, with support at $108 and resistance at $109.
Outlook remains positive with a consensus price target of $120.70, offering ~10% upside. Risks include competitive pressures in medical devices and macroeconomic volatility. Earnings beats in Q1 and Q2 2026 support growth, but margin compression and high P/E of 35.15 warrant caution for value-focused investors.
Avient Corporation (AVNT) trades at $45.69, up 7.13% with strong technical momentum. The stock shows consistent earnings beats with Q2 2026 EPS of $0.96 exceeding expectations by $0.07. Analyst consensus remains bullish with a $49.00 price target and 60% buy ratings. Recent quarterly dividend of $0.275 per share demonstrates shareholder returns while maintaining operational strength with $299M operating cash flow in 2026.
Outlook remains positive with improved full-year guidance and 20% adjusted EPS growth. Key risks include competitive pressures in chemical sector and potential margin compression. Upside potential exists toward $49-50 resistance zone, supported by strong fundamentals and institutional confidence in management's execution capabilities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Avient Corporation
Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.
Read more on AVNT →
